UNITED STATES SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~January~~April 2812, 2016

OxySure Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		000-54137		71-0960725
(State or other jurisdiction of incorporation or organization)		(Commission file number)		(IRS Employer Identification No.)

10880 John W. Elliott Drive, Suite 600 Frisco, TX 75033 (Address of Principal Executive Offices)

~~Frisco~~(972) 294-6450 (Registrant’s Telephone Number, TXIncluding ~~75033~~Area Code)

(Address of Principal Executive Offices)

(972) 294-6450

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

ITEM 7 5.0103 Amendments ~~Regulation~~to FDArticles ~~Disclosure~~of Incorporation or Bylaws; Change in Fiscal Year.

On April ~~January 27~~6, 2016, OxySure Therapeutics, Inc. (the “Company”), ~~the~~or ~~Board~~“OxySure”) offiled ~~Directors~~an ofas ~~the~~corrected ~~Company~~amendment to ~~and~~Article ~~certain~~Four ~~stockholders~~ of the Company’s ~~filed~~Articles ~~a letter~~of Incorporation with the ~~office~~Secretary of ~~U.S.~~State ~~Senator~~in ~~John~~Delaware. ~~Cornyn~~Pursuant ~~requesting referrals~~ to the ~~Securities and Exchange Commission and other authorities~~certificate toof ~~initiate~~amendment ~~investigations~~(the ~~into~~“Reverse ~~certain~~Split ~~manipulative~~Certificate ~~short~~of ~~selling~~Amendment”), ~~naked~~the ~~short~~Company ~~selling~~effected ora ~~other~~reverse ~~illegal~~split ~~short~~at ~~selling~~a ~~activities relating~~ratio ~~to the trading~~ of ~~the Company’s common stock~~1-for-50. The ~~Company’s~~Reverse ~~stock~~Split isCertificate ~~traded on OTCQB under the ticker symbol OXYS. A copy~~ of ~~the~~Amendment ~~letter~~ is ~~filed~~attached ~~herewith~~hereto as Exhibit 993.1 and incorporated herein by reference.

~~The~~In addition, the Company ~~also~~ filed aan ~~similar~~as ~~complaint~~corrected ~~directly~~amendment ~~with~~to Section 4.01 of Article Four of the ~~Securities~~Company’s ~~and~~Articles ~~Exchange~~of ~~Commission~~Incorporation. Pursuant onto ~~behalf~~the certificate of amendment (“Share Change Certificate of Amendment”) the Company increased the authorized shares of the Company’s ~~and~~common ~~all~~stock, ~~its~~par ~~stockholders~~value $0.0004 per share (“Common Stock”) to 500,000,000 shares. The Share ~~Company~~Change Certificate of Amendment is ~~seeking~~attached ~~full~~hereto ~~accountability~~as Exhibit 3.2 and ~~immediate~~incorporated ~~delivery~~herein ofby ~~all~~reference. ~~OXYS~~No ~~shares~~other ~~sold~~amendments ~~short~~were ~~over~~made ato ~~period~~the ofCompany’s ~~over~~Articles ~~fourteen~~of ~~months~~Incorporation.

The information contained in this Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

ITEM 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.		Description ~~of Exhibit~~
99.1		Letter dated January 26, 2016.
3.1		As corrected Certificate of Amendment, filed April 6, 2016, to the Company’s Articles of Incorporation
3.2		As corrected Certificate of Amendment, filed April 4, 2016, to the Company’s Articles of Incorporation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 28, 2016	OxySure Therapeutics, Inc.
Date: April 12, 2016	OxySure Therapeutics, Inc.
	By:	/s/ Julian T. Ross
	Name:	Julian T. Ross
	Title:	Chairman, Chief Executive Officer, President, and Chief Financial Officer

Filing Compare · OxySure Therapeutics, Inc.